Skip to main content
bioRxiv
  • Home
  • About
  • Submit
  • ALERTS / RSS
Advanced Search
New Results

NRX-101, A RAPID-ACTING ANTI-DEPRESSANT, DOES NOT CAUSE NEUROTOXICITY FOLLOWING KETAMINE ADMINISTRATION IN PRECLINICAL MODELS

William Jordan, Richard Siegel, Rajendra Kumar, View ORCID ProfileJonathan Javitt
doi: https://doi.org/10.1101/2022.06.18.496662
William Jordan
1Vet Path Services, Inc, 6450 Castle Drive, Mason, Ohio
DVM, PhD, DACVP
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Richard Siegel
2NeuroRx, 1201 N. Market Street, Suite 200, Wilmington, DE 19801
PhD
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Rajendra Kumar
3WuXi Apptec, Inc., Free Trade Zone, Pudong, China
PhD
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Jonathan Javitt
2NeuroRx, 1201 N. Market Street, Suite 200, Wilmington, DE 19801
M.D., M.P.H.
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • ORCID record for Jonathan Javitt
  • For correspondence: jjavitt@nrxpharma.com
  • Abstract
  • Full Text
  • Info/History
  • Metrics
  • Preview PDF
Loading

ABSTRACT

Background NMDA (N-Methyl-D aspartate) receptor antagonists have gained increasing attention as rapid-acting antidepressants. However, their use has been limited by potential neurotoxicity (Olney Lesions) and recent FDA guidance requires demonstration of safety on histologic parameters prior to initiation of human studies. D-cycloserine is a mixed NMDA agonist/antagonist awarded Breakthrough Therapy Designation and currently in clinical trials for the treatment of bipolar depression with suicidal ideation. The current study was designed to investigate the neurologic safety profile of D-cycloserine by itself and in combination with ketamine and lurasidone.

Methods Sprague Dawley female rats (n=106) were randomly divided into 7 study groups. Ketamine was administered via tail vein infusion. D-cycloserine and lurasidone were administered via oral gavage in escalating doses to a maximum of 2000 mg/kg DCS. To ascertain toxicity, dose escalation with three different doses of D-cycloserine/lurasidone was given in combination with ketamine. MK-801, a known neurotoxic NMDA antagonist, was administered as a positive control. Brain tissue was sectioned and stained with H&E and Fluorojade stains.

Results No fatalities were observed in any group. No microscopic abnormalities were found in the brain of animal subjects given ketamine, ketamine followed by DCS/lurasidone, or DCS/lurasidone alone. Neuronal necrosis, as expected, was seen in the MK-801 positive control group.

Conclusion NRX-101, a fixed-dose combination of D-cycloserine/lurasidone, when administered with or without prior infusion of IV ketamine was tolerated and did not induce neurotoxicity, even at maximum-tolerated doses of D-cycloserine.

HIGHLIGHTS

  • NRX-101, a fixed dose combination of D-cycloserine and lurasidone does not exhibit histologic neurotoxicity, even at maximum-tolerated doses

Competing Interest Statement

Drs Siegel and Javitt are employees and shareholders of NRx Pharmaceuticals, Inc. All data collection and interpretation was conducted by individuals with no propriety interest in the outcome of the research.

Footnotes

  • Statement of proprietary interest: Drs Siegel and Javitt are employees and shareholders of NRx Pharmaceuticals, Inc. All data collection and interpretation was conducted by individuals with no propriety interest in the outcome of the research.

Copyright 
The copyright holder for this preprint is the author/funder, who has granted bioRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY-ND 4.0 International license.
Back to top
PreviousNext
Posted June 20, 2022.
Download PDF
Email

Thank you for your interest in spreading the word about bioRxiv.

NOTE: Your email address is requested solely to identify you as the sender of this article.

Enter multiple addresses on separate lines or separate them with commas.
NRX-101, A RAPID-ACTING ANTI-DEPRESSANT, DOES NOT CAUSE NEUROTOXICITY FOLLOWING KETAMINE ADMINISTRATION IN PRECLINICAL MODELS
(Your Name) has forwarded a page to you from bioRxiv
(Your Name) thought you would like to see this page from the bioRxiv website.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Share
NRX-101, A RAPID-ACTING ANTI-DEPRESSANT, DOES NOT CAUSE NEUROTOXICITY FOLLOWING KETAMINE ADMINISTRATION IN PRECLINICAL MODELS
William Jordan, Richard Siegel, Rajendra Kumar, Jonathan Javitt
bioRxiv 2022.06.18.496662; doi: https://doi.org/10.1101/2022.06.18.496662
Reddit logo Twitter logo Facebook logo LinkedIn logo Mendeley logo
Citation Tools
NRX-101, A RAPID-ACTING ANTI-DEPRESSANT, DOES NOT CAUSE NEUROTOXICITY FOLLOWING KETAMINE ADMINISTRATION IN PRECLINICAL MODELS
William Jordan, Richard Siegel, Rajendra Kumar, Jonathan Javitt
bioRxiv 2022.06.18.496662; doi: https://doi.org/10.1101/2022.06.18.496662

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
  • Tweet Widget
  • Facebook Like
  • Google Plus One

Subject Area

  • Pharmacology and Toxicology
Subject Areas
All Articles
  • Animal Behavior and Cognition (4688)
  • Biochemistry (10379)
  • Bioengineering (7695)
  • Bioinformatics (26372)
  • Biophysics (13547)
  • Cancer Biology (10722)
  • Cell Biology (15460)
  • Clinical Trials (138)
  • Developmental Biology (8509)
  • Ecology (12843)
  • Epidemiology (2067)
  • Evolutionary Biology (16886)
  • Genetics (11416)
  • Genomics (15493)
  • Immunology (10638)
  • Microbiology (25254)
  • Molecular Biology (10240)
  • Neuroscience (54591)
  • Paleontology (402)
  • Pathology (1671)
  • Pharmacology and Toxicology (2899)
  • Physiology (4355)
  • Plant Biology (9263)
  • Scientific Communication and Education (1588)
  • Synthetic Biology (2561)
  • Systems Biology (6789)
  • Zoology (1470)